Drs. Barna and Hughes are both clinical assistant professors in the Department of Pharmacy Practice and Administration at Ernest Mario School of Pharmacy, Rutgers—The State University of New Jersey in Piscataway, New Jersey.
Alzheimer's disease (AD) is an incurable, irreversible, and progressive neurologic disease and is the most common cause of dementia. According to the US Census 2000, it was estimated that nearly 4.5 million Americans had AD. As the baby boom generation of the United States ages, the prevalence of this debilitating disease, primarily associated with advancing age, is projected to triple to affect an estimated 13.2 million individuals by 2050.1 The National Center for Health Statistics data indicate that AD surpassed diabetes to become the sixth leading cause of death in the United States in 2006, with an estimated 72,914 Americans succumbing to this disease.2 The growing incidence of AD in the United States represents a mounting public health problem and mandates that clinicians have a strong understanding of both the disease and various treatment modalities.
The current cause of AD is not fully known, but the amyloid cascade hypothesis is the leading hypothesis describing the pathogenesis of AD. It states that an imbalance exists between the production and clearance of â-amyloid peptide (a peptide produced during normal cell metabolism) in the brain.3 The accumulation of â-amyloid peptide causes damage to the neurons through multiple mechanisms including inflammation, production of neuritic plaques and neurofibrillary tangles, and neuron toxicity due to excessive stimulation of the N-methyl-D-aspartate (NMDA) receptor by glutamate. Damage to neurons leads to the depletion of neurotransmitters, such as acetylcholine, norepinephrine, and serotonin, causing the clinical manifestations of AD.4
AD currently has no cure, and pharmacologic therapy focuses on regulation of neurotransmittors, not on halting or preventing the underlying cause of the disease. Therefore, nonpharmacologic behavioral interventions are the mainstay of therapy for patients and families living with AD. Behavioral modification, simplification of demands and tasks, increased physical activity, and education and counseling for family members are important components of a multidisciplinary approach to caring for the AD patient. Pharmacologic interventions can help to slow the progression of the disease, reduce symptoms, and improve quality of life. Both therapeutic modalities are often used in conjunction with each other because of the profound effects of AD on the patient as well as family members and caregivers.
Because nonpharmacologic treatments are the mainstay of caring for the patient with AD, the pharmacist plays a pivotal role in reinforcing important counseling points with family members and caregivers. Education for the AD patient's caregiver has shown to improve caregiver satisfaction, knowledge, and confidence. It also has been known to potentially delay nursing home placement, although it has no effect on disease severity or patient outcome.5
Behavioral modification strategies, including limiting wardrobe choices and accessories, encouraging showering instead of bathing because of ease, and eliminating unnecessary furniture that could pose an environmental hazard and increase the patient's risk of fall, are important interventions to minimize harm to the patient. Confrontation and aggression can often be avoided by simplifying tasks and demands. Brain exercises and increasing physical activity may increase cerebral blood flow and oxygen consumption, resulting in improvements in cognition. Ultimately, the caregiver should be reminded that sudden declines in mentation should be referred to a health care provider for management.
Summary of Pharmacologic Agents Used in the Treatment of Alzheimer's Disease
Dosage Forms Available
Starting Dose and Schedule
Effective Daily Dose
Donepezil (Aricept; Aricept ODT)
5-10 mg once daily in the evening with or without food
5 mg over 4-6 weeks
Galantamine (Razadyne; Razadyne ER)
Tablets and oral solution (immediate release); capsules (ER)
4 mg twice a day with food (immediate release); 8 mg once daily in the morning, preferably with food (ER)
8 mg every 4 weeks
Rivastigmine (Exelon; Exelon Patch)
Capsules and oral solution; transdermal patch
1.5 mg twice a day (oral formulations); 4.6 mg/24 hours (transdermal patch)
6-12 mg (oral formulations); 9.5 mg (transdermal patch)
3 mg every 2 weeks (oral formulations); 9.5 mg/24 hours after 4 weeks (transdermal patch)
Tablets and oral solution
5 mg once a day
5 mg every week
The American College of Physicians and the American Academy of Family Physicians recently published a clinical practice guideline with recommendations for pharmacologic treatment in the AD patient. The document emphasizes an individualized approach to choosing to initiate pharmacologic therapy, based on evaluating the patient's benefits and risks of treatment. Further, because of limited clinical trial evidence comparing the efficacy of available therapeutic agents, drug therapy selection should be based on ease of use, adverse effect profile, patient tolerability, and cost of medication.6
For patients with mild-to-moderate AD, cholinesterase inhibitors are the agents with the strongest evidence of efficacy in treating cognitive symptoms, according to the American Association for Geriatric Psychiatry.7 Because a primary pathology of AD is a deficiency in acetylcholine, agents in this category exert their pharmacologic effect by inhibiting the enzyme acetylcholinesterase, reducing the hydrolysis of acetylcholine and subsequently increasing levels of acetylcholine available in the synaptic space. Four agents in this category have been approved by the FDA: tacrine (Cognex), donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne). No strong clinical evidence exists indicating that one agent is superior in efficacy to another. Due to complex dosing and safety concerns, however-specifically the risk of causing hepatoxicity- tacrine is generally not recommended for routine use.
Other common side effects associated with all of these agents are significant gastrointestinal adverse reactions, including nausea, vomiting, anorexia, and weight loss. To minimize the risk of these unwanted side effects, common strategies include starting with the lowest doses, using a slow titration schedule, using alternative dosage forms (ie, transdermal patch), and taking medications with food. Refer to the Table for a comparison of available dosage forms, dosing, and titration schedules for the various agents.
Memantine (Namenda) is currently the only available NMDA antagonist approved for the treatment of moderateto- severe AD. Memantine is thought to exert its pharmacologic effect by binding to glutamate receptors to attenuate glutaminergic excitotoxicity and provide symptomatic improvements in memory and daily function. Memantine dosing information can be found in the Table. Memantine is generally well tolerated, although common side effects include dizziness, headache, hallucinations, confusion, and constipation. Because memantine is not hepatically metabolized, it is unlikely to be associated with significant hepatic drug–drug interactions. Still, caution should be taken with concomitant administration of other medications likely to have an effect at the NMDA receptor, such as dextromethorphan.
Memantine can be used as monotherapy, or in combination with the cholinesterase inhibitors, to slow the progression of AD. Results of clinical trials in patients with moderate-to-severe AD have shown the combination of memantine plus cholinesterase inhibitor may have a modest effect on improving cognition, slowing the decline in activities of daily living, and reducing the frequency of the development of new behavioral symptoms when compared with placebo.8 The decision to combine agents of these 2 classes should be patient specific.
Behavioral symptoms, including depression, social withdrawal, and mood change, occur early in the course of AD, whereas agitation, irritability, and anxiety become more pronounced as the disease progresses.9 Atypical antipsychotics such as olanzapine (Zyprexa) and risperidone (Risperdal) have shown comparable efficacy in treating behavioral symptoms in patients with AD.10 These agents are preferred over conventional antipsychotics due to a lower risk of extrapyramidal side effects.4 Approximately 20% of patients receiving olanzapine and risperidone discontinued treatment, because of adverse effects, including sedation and extrapyramidal side effects, which may offset any benefit of these medications. 10 In addition, current atypical antipsychotics have a black box warning advising against using in patients with dementia-related psychosis because of a potential increased risk of death.11-13
It is important that health care professionals carefully evaluate the risks and benefits associated with using antipsychotic medications in managing patients with AD. Carbamazepine (Tegretol) and valproic acid (Depakote) also may be useful in managing behavioral symptoms. 4
Selective serotonin reuptake inhibitors are preferred for the management of depression in patients with AD. Tricyclic antidepressants have significant anticholinergic adverse effects and should be avoided.9 Short-acting benzodiazepines can be useful for managing nonpsychosis-related agitation in patients with AD; however, long-term use should be avoided due to the potential for sedation and impaired cognition.9
AD is a growing public health concern. Pharmacists can play an active role in counseling patients and caregivers on realistic outcome expectations, medication costs, and potential adverse effects from both pharmacologic and nonpharmacologic therapies. Pharmacists also can proactively identify concomitant medications that may affect cognitive function, such as sedatives and medications with anticholinergic adverse effects, as well as recommend alternative therapies.
In Seniors: Consider CMV Serostatus
When Recommending Flu Vaccine
Older people who have cytomegalovirus seem to have less robust responses to the trivalent influenza vaccine than those who do not have CMV.
News from the year's biggest meetings
Clinical features with downloadable PDFs